# Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

> **NCT02939599** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** QCC374

## Key facts

- **NCT ID:** NCT02939599
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-01
- **Primary completion:** 2018-11-06
- **Final completion:** 2018-11-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was terminated early for strategic reasons. Only Part I of the study was completed.
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939599, "Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02939599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*